ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AG-181

A development code.

Its studies are mostly in Phenylketonurias, led by Agios Pharmaceuticals.

Furthest: phase 1, since Feb 23, 20242 company-led studies, 1 open or runningNext primary completion: Jan 17, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Agios Pharmaceuticals21 open or runningphase 1since Feb 23, 2024Feb 23, 2024Jan 17, 2028phase 1 · NCT07241234

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06286033 · 88 enrolled · United States
  2. Nov 17, 2025Phase 1 study in PhenylketonuriasNCT07241234 · 20 planned · United States, Poland

Ahead

  1. Jan 17, 2028Primary completion: phase 1 study in PhenylketonuriasNCT07241234

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07241234Phenylketonurias · United States, Poland1RecruitingJan 17, 202820
NCT06286033Healthy Volunteers · United States1CompletedOct 9, 202588

How it is read

Names in the registry

  • “AG-181”, 2 entries

Codes read as this program: AG181.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
AG-181 (Agios Pharmaceuticals): development program | ClinicalTrials.gg